Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Microphthalmia
- Sponsor
- Baylor College of Medicine
- Enrollment
- 3000
- Locations
- 1
- Primary Endpoint
- Stage 3
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The investigators are inviting families to take part in a research study that will help us better understand the physical characteristics associated with children who have Microphthalmia, Anophthalmia, and Coloboma (MAC) and how changes in their DNA sequence, called genetic mutations, play a role in the risk of developing MAC
Detailed Description
This study is focused on gathering data on individuals diagnosed with some of the more common visually threatening congenital eye defects collectively referred to as MAC complex; anophthalmia (total absence of the globe), microphthalmia (anomalously small eye in the orbit), and coloboma (failure of the closure of the fetal fissure). Our long-term goal is to improve prevention efforts for and clinical management of MAC. The objectives of the current study are to 1) better define the MAC phenotype and 2) characterize the role of known and newly identified pathogenic genetic variants that confer MAC susceptibility. To do this, the investigators are leveraging resources to identify MAC cases through the Texas Birth Defects Registry (TBDR), Texas Children's Hospital (TCH), and through direct referrals from our study partners. The investigators intend to conduct secondary analyses by leveraging the existing collaborative relationship with the New York State Newborn Screening Program (NYSNSP). Also, the investigators are utilizing the resources of the National Institutes of Health (NIH) Clinical Center to comprehensively phenotype cases with MAC, and the National Eye Institute (NEI) Ophthalmic Genomics Laboratory to identify genetic variants underlying MAC phenotypes.
Investigators
Philip J Lupo
Principal Investigator, Professor of Pediatrics; Director, Epidemiology and Population Sciences Program
Baylor College of Medicine
Eligibility Criteria
Inclusion Criteria
- •All MAC cases
- •Parents of the above children.
- •Siblings of the above children.
- •English or Spanish speaking.
Exclusion Criteria
- •All subjects who do not meet the inclusion criteria listed above.
Outcomes
Primary Outcomes
Stage 3
Time Frame: End of study, on or before 12/31/2032
We are working closely with collaborators at the NIH Clinical Center to conduct deep phenotyping of children with MAC, who do not have a diagnosed syndrome, as well as their first-degree family members. This may include complete eye examinations, neuropsychological testing, hearing evaluation, additional facial imaging, echocardiograms, and magnetic resonance imaging (MRI) of the brain.
Stage 2
Time Frame: End of study, on or before 12/31/2032
We are also conducting in-person, virtual, or remote physical assessments to obtain detailed phenotypic information including three-dimensional (3D) digital imaging to capture facial phenotype of cases and their parents. We also collect blood samples during this stage.
Stage 1
Time Frame: End of study, on or before 12/31/2032
We are conducting interviews to collect detailed pregnancy, medical and family histories; review medical records to identify cases with chromosomal abnormalities or other syndromic diagnosis (that were not identified by the TBDR) and associated malformations, as well as to assess clinical course; and collect saliva samples that may be used to extract DNA to be analyzed for genetic mutations.